Amur Minerals Corporation Exercise of Warrants and Issue of Equity (8698X)
03 September 2020 - 8:00AM
UK Regulatory
TIDMAMC
RNS Number : 8698X
Amur Minerals Corporation
03 September 2020
3 September 2020
AMUR MINERALS CORPORATION
(AIM: AMC)
Exercise of Warrants and Issue of Equity
Amur Minerals Corporation ("Amur" or the "Company"), the
nickel-copper sulphide mineral exploration and resource development
company focused on the far east of Russia, announces that, pursuant
to the fixed term loan note agreement entered into with Plena
Global Opportunities LLC ("Investor") and announced on 12 March
2020, the Investor has elected to convert 6,500,000 warrants
("Warrants") at the warrant exercise price of 1.43 pence per share
providing the Company GBP92,950. The Investor has 4,723,776
warrants remaining. The Company repaid the loan note in full on 4
May 2020.
Application will be made to the London Stock Exchange plc for
6,500,000 new Ordinary Shares to be admitted to trading on the AIM
market with admission expected to occur on or around 8 September
2020. The new Ordinary Shares rank pari passu in all respects with
the existing Ordinary Shares including the right to receive any
dividend or other distribution thereafter declared, made or paid.
There are no Ordinary Shares held in treasury. Therefore, the total
number of voting rights in the Company, following the issue of
6,500,000 new Ordinary Shares is 1,371,026,775.
Market Abuse Regulation (MAR) Disclosure
Certain information contained in this announcement would have
been deemed inside information for the purposes of Article 7 of
Regulation (EU) No 596/2014 until the release of this
announcement.
Company Nomad and Broker Public Relations
Amur Minerals S.P. Angel Corporate Finance Blytheweigh
Corp. LLP
Robin Young CEO Richard Morrison Megan Ray
Soltan Tagiev Tim Blythe
+44 (0) 7981 126 +44 (0) 20 7138
818 +44 (0) 20 3470 0470 3203
For additional information on the Company, visit the Company's
website, www.amurminerals.com .
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
IOEUPUBGBUPUGQP
(END) Dow Jones Newswires
September 03, 2020 02:00 ET (06:00 GMT)
Crism Therapeutics (AQSE:AMC.GB)
Historical Stock Chart
Von Jun 2024 bis Jul 2024
Crism Therapeutics (AQSE:AMC.GB)
Historical Stock Chart
Von Jul 2023 bis Jul 2024